Alexion Pharmaceuticals, Inc.
Treating muscle weakness with alkaline phosphatases

Last updated:

Abstract:

The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.

Status:
Grant
Type:

Utility

Filling date:

31 Mar 2017

Issue date:

30 Nov 2021